Cargando…
Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [(13)C(8)]‐evacetrapib as a tracer
This open‐label, single‐period study in healthy subjects estimated evacetrapib absolute bioavailability following simultaneous administration of a 130‐mg evacetrapib oral dose and 4‐h intravenous (IV) infusion of 175 µg [(13)C(8)]‐evacetrapib as a tracer. Plasma samples collected through 168 h were...
Autores principales: | Cannady, Ellen A., Aburub, Aktham, Ward, Chris, Hinds, Chris, Czeskis, Boris, Ruterbories, Kenneth, Suico, Jeffrey G., Royalty, Jane, Ortega, Demetrio, Pack, Brian W., Begum, Syeda L., Annes, William F., Lin, Qun, Small, David S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064742/ https://www.ncbi.nlm.nih.gov/pubmed/26639670 http://dx.doi.org/10.1002/jlcr.3358 |
Ejemplares similares
-
Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
por: Small, David S., et al.
Publicado: (2016) -
Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects
por: Small, David S., et al.
Publicado: (2016) -
A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State
por: Small, David S., et al.
Publicado: (2015) -
CETP inhibitor evacetrapib enters mouse brain tissue
por: Phénix, Jasmine, et al.
Publicado: (2023) -
CYP‐mediated drug–drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome
por: Cannady, Ellen A., et al.
Publicado: (2015)